Company Overview of FORUM Pharmaceuticals Inc.
FORUM Pharmaceuticals Inc. manufactures life-changing medicines for the treatment of serious brain diseases. Its products include Gamma secretase modulation, an approach to reduce Abeta42 production; HDAC program, an activity of HDAC has an impact on brain diseases that display abnormalities in the gene transcription; PDE 10 program, an investigational phosphodiesterase inhibitor; and alpha-7 Receptor agonists, an orally administered encenicline hydrochloride. The company provides its therapies for Alzheimer's disease and Schizophrenia. The company was formerly known as EnVivo Pharmaceuticals, Inc. and changed its name to FORUM Pharmaceuticals Inc. in April, 2014. FORUM Pharmaceuticals Inc. ...
500 Arsenal Street
Watertown, MA 02472
Founded in 2001
Key Executives for FORUM Pharmaceuticals Inc.
Chief Executive Officer, President and Director
Chief Financial Officer and Senior Vice President
Chief Scientific Officer and Senior Vice President of Research
Senior Vice President and General Counsel
Chief Medical Officer and Senior Vice President of Clinical Development
Compensation as of Fiscal Year 2014.
FORUM Pharmaceuticals Inc. Key Developments
FORUM Pharmaceuticals Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 10:00 AM
Mar 25 15
FORUM Pharmaceuticals Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 10:00 AM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Deborah Dunsire, Chief Executive Officer, President and Director.
FORUM Pharmaceuticals Inc. Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015
Feb 18 15
FORUM Pharmaceuticals Inc. Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015 . Venue: JW Marriott Essex House, 160 Central Park South, b/w 6th & 7th Avenue, New York, New York, United States.
FORUM Pharmaceuticals Inc. Initiates Phase 2a Clinical Trial of FRM-0334 in Frontotemporal Dementia with GRN Mutation
Feb 10 15
FORUM Pharmaceuticals Inc. announced dosing of the first patient in a Phase 2a proof of mechanism clinical trial to evaluate FORUM's investigational therapy FRM-0334 in patients with the ultra-orphan rare disease frontotemporal dementia with granulin mutation (FTD-GRN). FTD-GRN is a rare, early-onset and rapidly progressive neurodegenerative brain disorder that can affect behavior, cognition, language and motor skills. FTD-GRN results from genetic mutations in the granulin (GRN) gene that lead to less progranulin protein, which is believed to play an important role in neuron survival. FRM-0334 may have therapeutic potential to partially reverse the loss of protein function in FTD-GRN. The randomized, double-blind, placebo-controlled, dose-escalating Phase 2a clinical trial will evaluate the safety, tolerability and pharmacodynamic effects of two doses of FRM-0334 in subjects with prodromal to moderate FTD-GRN. Primary endpoints will assess the safety and tolerability of FRM-0334 in subjects with the FTD-GRN genotype, as well as effects of FRM-0334 on plasma and cerebrospinal fluid progranulin concentrations. FORUM anticipates enrolling subjects at multiple sites in the United States and Western Europe for the trial. The Company has previously completed a Phase 1 study of FRM-0334 in Europe, where it was found to be well tolerated at all doses tested.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|